Analyst Ratings for [APLT] Applied Therapeutics, Inc.

12/23/24	Downgrades	Outperform Mkt Perform	X
APLT Applied Therapeutics William Blair
12/2/24	Downgrades	Buy Neutral	X
APLT Applied Therapeutics UBS
$13 $2
11/29/24	Downgrades	Outperform Sec Perform	X
APLT Applied Therapeutics RBC Capital Mkts
$12 $4
7/31/24	Initiated	Outperform	X
APLT Applied Therapeutics William Blair
3/26/24	Initiated	Outperform	X
APLT Applied Therapeutics RBC Capital Mkts
$12
2/22/24	Initiated	Outperform	X
APLT Applied Therapeutics Leerink Partners
$12
1/4/22	Downgrades	Overweight Eq Weight	X
APLT Applied Therapeutics Barclays
$44 $7
6/25/21	Resumed	Neutral	X
APLT Applied Therapeutics Goldman
$18
6/10/19	Initiated	Buy	X
APLT Applied Therapeutics Citigroup
$29
6/10/19	Initiated	Outperform	X
APLT Applied Therapeutics Cowen
6/10/19	Initiated	Outperform	X
APLT Applied Therapeutics Robert W. Baird
$24

APLT Applied Therapeutics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.